CONTACT

Team Leader: Massimo Levrero
Bâtiment Inserm
151 Cours Albert Thomas
69424 Lyon Cedex 03

massimo.levrero@inserm.fr

04 72 68 19 79

04 72 68 19 70 (secretariat)
LEVRERO Massimo
Professor of Medicine (PUPH) - MD (UCLB - HCL)
massimo.levrero@inserm.fr
ZEISEL Mirjam
CR Inserm
mirjam.zeisel@inserm.fr
PLISSONNIER Marie-Laure
Research engineer Inserm
marie-laure.plissonnier@inserm.fr
GUERRIERI Francesca
Postdoctoral fellow
francesca.guerrieri@inserm.fr
ALFANO Vincenzo
Postdoctoral fellow
vincenzo.alfano@inserm.fr
PATUREL Alexia
Ph.D Student
alexia.paturel@inserm.fr
CHOUIK Yasmina
Ph.D Student
yasmina.chouik@inserm.fr
THIRION Margot
Ph.D Student
margot.thirion@inserm.fr
CASUSCELLI Franscesca
Post-doctoral fellow

franscesca.casuscelli@inserm.fr

CARON de FROMENTEL Claude

DR2 INSERM

claude.de-fromentel@inserm.fr

MERLE Philippe

Professor of Medicine – MD-PhD (UCBL-HCL)

philippe.merle@inserm.fr

CORTAY Jean-Claude

CRCN CNRS

jean-claude.cortay@inserm.fr

MOHKAM Kayvan

Praticien Hospitalo-Universitaire (PHU) – MD-PhD (UCBL-HCL)

Kayvan.mohkam@chu-lyon.fr
Voir les objectifs et projets Voir les publications

OBJECTIVES

Our team aim to utilize cutting edge innovative technologies and to link high technology to clinical application by extensive validation of the new findings in patient samples from relevant clinical settings. Our team success and its translational value will very much depend on the access to liver samples from well-defined categories of patients. This will be achieved through the collaboration with a vast net of leading clinical groups in HBV and HCC research in Italy and France. Altogether, our research efforts will generate new knowledge and provide new insights on the molecular pathogenesis of virus-related HCCs but will also, hopefully, provide data for the rationale use of anti-Ezh2/PRC2 in HCC treatment and lead to the development of biomarkers for early diagnosis, prognostication and treatment allocation of liver cancer patients. 

PROJETS

HCC is one of the most frequent tumors worldwide and due to its poor prognosis, is the 2nd cause of cancer death worldwide. In Europe, HCC incidence and mortality rates are of 65,000 and 60,240 cases in Europe, respectively.

HCC development is driven by multiple viruses (HBV, HCV) and chronic metabolic alterations leading to chronic inflammation, DNA damage, epigenetic and genetic changes that affect both “common” and “etiology specific” oncogenic pathways. Importantly, whereas mutations and chromosomal aberrations, with the only exception of TERT promoter mutation, have been consistently found in tumor tissues, deregulation of signaling pathways and epigenetic changes (DNA methylation, post-translational histone modifications and noncoding RNA-mediated silencing pathways) are also detected early in the natural history of HCC development, at the stage of chronic hepatitis, cirrhosis or dysplastic nodules. Epigenetic changes include, occur early in the development of HCC.

 

The EpiHep team investigates the epigenetic changes that precede and accompany HCC development and progression mainly, but not exclusively, in the setting of HBV chronic liver diseases.

Specific research projects aim to:

a) define the contribution of the viral protein HBx and HBc in HBV pathogenicity, liver tumors development and progression;

b) study the expression profiles of exhausted antigen specific CD8 lymphocytes in chronic HBV carriers and HBV-related HCCs and test new pharmacological correction strategies;

c) identify the gene network controlled by the PRC2/Ezh2 complex in normal and neoplastic liver cells and to investigate the functional consequences of Ezh2 genetic knockdown and pharmacological manipulation;

d) identify genes and ncRNAs co-regulated by IL6/STAT3 and the PRC2 complex in HBV, HCV and NASH-related cancers and investigate their modulation by AMPK and metformin.

PUBLICATIONS

 

2020

Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA replication. Abeywickrama-Samarakoon N, Cortay JC, Sureau C, Müller S, Alfaiate D, Guerrieri F, Chaikuad A, Schröder M, Merle P, Levrero M, Dény P. Nat Commun. 2020 Jan 21;11(1):419. doi: 10.1038/s41467-020-14299-9.

A combined small molecule and loss-of-function screen uncovers estrogen 2 receptor alpha and CAD as host factors for HDV infection and antiviral targets. Verrier ER,…, Zeisel MB,…, Baumert TF. Gut 2020; 69(1):158-167. doi: 10.1136/gutjnl-2018-317065.

A functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity. Herzog K, Bandiera S,..., Zeisel MB. Gut 2020; 69(2):380-392. doi: 10.1136/gutjnl-2018-317423.

2019

Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, Loglio A, Facchetti F, Lampertico P, Levrero M, Zoulim F. J Hepatol. 2019 Apr;70(4):615-625. doi: 10.1016/j.jhep.2018.11.030.

The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of  HBx N terminus in vitro. Salpini R,…, Levrero M,…, Svicher V. Clin Microbiol. Infect. 2018 Nov;pii: S1198-743X(18)30744-4. doi: 10.1016/j.cmi.2018.11.017.

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells. Di Cocco S, Belloni L, Nunn ADG, Salerno D, Piconese S, Levrero M, Pediconi N. J Vis Exp. 2019 Jul 18;(149). doi: 10.3791/59843.

EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells. Pediconi N, Salerno D, Lupacchini L, Angrisani A, Peruzzi G, De Smaele E, Levrero M, Belloni L. Cell Death Dis. 2019 Jul 8;10(7):518. doi: 10.1038/s41419-019-1755-2.

Effect of food preservatives and additives in promoting intestinal inflammation. Laudisi F, Di Fusco D, Dinallo V, Stolfi C, Di Grazia A, Marafini I, Colantoni A, Ortenzi A, Alteri C, Guerrieri F, Ceccherini-Silberstein F, Federici M, Monteleone I, and Monteleone G. Cell Mol Gastroenterol Hepatol. 2019;7(2):457-473. doi: 10.1016/j.jcmgh.2018.09.002.

Microglia-Derived Microvesicles Affect Microglia Phenotype in Glioma. Grimaldi A, Serpe C, Chece G, Nigro V, Sarra A, Ruzicka B, Relucenti M, Familiari G, Ruocco G, Pascucci GR, Guerrieri F, Limatola C, Catalano M. Front Cell Neurosci. 2019 Feb;13:41. doi: 10.3389/fncel.2019.00041.

HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Hamdane N, Jühling F,…, Zeisel MB,…, Baumert TF. Gastroenterology. 2019 Jun;156(8):2313-2329.e7. doi:10.1053/j.gastro.2019.02.03.

In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF. Antiviral Res. 2019 Feb;162:136-141. doi: 10.1016/j.antiviral.2018.12.018.

Combined analysis of metabolome, proteomes, and transcriptomes of HCV-infected cells and liver to identify pathways associated with disease development. Lupberger J,…, Zeisel MB,…, Baumert TF. Gastroenterology. 2019 Apr;pii: S0016-5085(19)35670-7. doi: 10.1053/j.gastro.2019.04.003.

IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection. Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung KH, Baumert TF. Hepatology. 2019 May;doi: 10.1002/hep.30699.

A global scientific strategy to  cure hepatitis B. Revill PA,…, Levrero M,…, Thimme R. Lancet Gastroenterol Hepatol. 2019 Apr; pii: S2468-1253(19)30119-0. doi: 10.1016/S2468-1253(19)30119-0. Review.

Update of the statements on biology and clinical impact of occult hepatitis b virus infection. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS. J Hepatol. 2019 Apr; pii: S0168-8278(19)30259-4. doi: 10.1016/j.jhep.2019.03.034. Review.

Non-invasive biomarkers for chronic hepatitis B virus infection management. Charre C, Levrero M, Zoulim F, Scholtès C. Antiviral Res. 2019 Sep;169:104553. doi:10.1016/j.antiviral.2019.104553. Review.

Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis. Bonnin M,...., Merle P,…., Lebecque S. J Hepatol. 2019 Jun 18. pii: S0168-8278(19)30351-4. doi: 0.1016/j.jhep.2019.05.031.

Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome. Wang H,..., Merle P,..., Soussan P.  Hepatol Int. 2019 Jul;13(4):454-467. doi: 10.1007/s12072-019-09950-7. 

Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Ca(v)3.2 T-type voltage-gated calcium channels and Ca(2+) influx. Jimenez H,., Merle P,., Pasche BC. EBioMedicine. 2019 Jun;44:209-224. doi:10.1016/j.ebiom.2019.05.034. 

In vitro transformation of primary human hepatocytes: Epigenetic changes and stemness properties. Pez F, Gifu P, Degli-Esposti D, Fares N, Lopez A, Lefrançois L, Michelet M, Rivoire M, Bancel B, Sylla BS, Herceg Z, Merle P, Caron de Fromentel C. Exp Cell Res. 2019 Nov 15;384(2):111643. doi: 10.1016/j.yexcr.2019.111643.

Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Roger E, Martel S,..., Mohkam K, Mabrut JY,..., Bartholin L. Cell Death Dis. 2019 Nov 25;10(12):886. doi: 10.1038/s41419-019-2116-x.

2018

Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. Belloni L,…, Guerrieri F,…, Levrero M, Pediconi N. Sci Rep. 2018 Sep;8(1):13638. doi: 10.1038/s41598-018-31835-2. 

Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Iebba V, Guerrieri F, Di Gregorio V, Levrero M, Gagliardi A, Santangelo F, Sobolev AP, Circi S, Giannelli V, Mannina L, Schippa S, Merli M. Sci Rep. 2018 May;8:8210. doi: 10.1038/s41598-018-26509-y.

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Van Renne N,…, Zeisel MB,…, Lupberger J. Gut. 2018 Feb; 67(5):953-962.  doi: 10.1136/gutjnl-2016-312270.

Hepatocellular carcinoma-associated depletion of the netrin-1 receptor Uncoordinated Phenotype-5A (UNC5A) skews the hepatic unfolded protein response towards prosurvival outcomes. Barnault R, Lahlali T, Plissonnier ML, Romero-López C, Laverdure N, Ducarouge  B, Rivoire M, Mehlen P, Zoulim F, Parent R. Biochem Biophys Res Commun. 2018 Jan;495(4):2425-2431. doi: 10.1016/j.bbrc.2017.12.129.

Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes. Verrier ER,…, Zeisel MB,…, Baumert TF. Hepatology. 2018 Nov;68(5):1695-1709. doi: 10.1002/hep.30054.

Enteric Delivery of Regenerating Family Member 3 alpha Alters the Intestinal Microbiota and Controls Inflammation in Mice With Colitis. Darnaud M,…, Guerrieri F,…, Faivre J. Gastroenterology. 2018 Mar;154(4):1009-1023.e14. doi: 10.1053/j.gastro.2017.11.003.

A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome. Voeltzel T, Flores-Violante M,..., Caron de Fromentel C, Maguer-Satta V. Cell Death Dis. 2018 Sep 27;9(10):1011. doi: 10.1038/s41419-018-1042-7.

Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. Komas NP, Ghosh S,..., Merle P,..., Cortay JC, Kay AC, Dény P. PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006377. doi: 10.1371/journal.pntd.0006377.

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape. Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF. Gut. 2018 Apr;67(4):736-745. doi: 10.1136/gutjnl-2016-312577.Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. Levrero M, Subic M, Villeret F, Zoulim F. Curr Opin Virol. 2018 Jun;30:80-89. doi: 10.1016/j.coviro.2018.04.006. Review.

Hepatitis B. Zoulim F, Levrero M, Testoni B. Nat Rev Gastroenterol Hepatol. 2018 Sep; doi: 10.1038/s41575-018-0060-3. Review.

[Hepatitis delta virus replication and the role of the small hepatitis delta protein S-HDAg]. Abeywickrama-Samarakoon N, Cortay JC, Sureau C, Alfaiate D, Levrero M, Dény P. Med Sci (Paris). 2018 Oct;34(10):833-841. doi: 10.1051/medsci/2018209. Review.

Non-Coding RNAs and Hepatitis  C Virus-Induced Hepatocellular Carcinoma. Plissonnier ML, Herzog K, Levrero M, Zeisel MB. Viruses. 2018 Oct;10(11). pii: E591. doi: 10.3390/v10110591. Review.

Tight junction proteins in gastrointestinal and liver disease. Zeisel MB, Dhawan P, Baumert TF. Gut 2018 Oct; pii: gutjnl-2018-316906. doi: 10.1136/gutjnl-2018-316906. Review.

miR-122-regulated metabolic circuits: micro-management of lipid metabolism in the human liver. Zeisel MB, Plissonnier ML, Levrero M. Non-Coding RNA Investigation 2018 Oct;10(11). pii: E591. doi: 10.3390/v10110591. Review.

Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design. Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF. Front Immunol. 2018 Jun;9:1436. doi: 10.3389/fimmu.2018.01436. Review.

Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Therap Adv Gastroenterol. 2018 Mar 21;11:1756284818759483. doi: 10.1177/1756284818759483. eCollection 2018. Review.

[Risk of hepatocellular carcinoma after hepatitis C virus cure with direct-acting antivirals: the next challenges]. Hamdane N, Baumert TF, Zeisel MB. Med Sci (Paris). 2018 May;34(5):391-394. doi: 10.1051/medsci/20183405007. Review.

2017

PRMT5 Restricts Hepatitis B Virus Replication via Epigenetic Repression of cccDNA Transcription and Interference with pgRNA Encapsidation. Zhang W, Chen J, Wu M, Zhang X, Zhang M, Yue L, Li Y, Liu J, Li B, Shen F, Wang Y, Bai L, Protzer U, Levrero M, Yuan Z. Hepatology. 2017 Feb 25. doi: 10.1002/hep.29133.

Genome-wide identification of direct HBx genomic targets. Guerrieri F, Belloni L, D'Andrea D, Pediconi N, Le Pera L, Testoni B, Scisciani C, Floriot O, Zoulim F, Tramontano A, Levrero M. BMC Genomics. 2017 Feb 17;18(1):184. doi: 10.1186/s12864-017-3561-5.

Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Fisicaro P, Barili V, Montanini B, Acerbi G, Ferracin M, Guerrieri F, Salerno D, Boni C, Massari M, Cavallo MC, Grossi G, Giuberti T, Lampertico P, Missale G, Levrero M, Ottonello S, Ferrari C. Nat Med. 2017 Feb 6. doi: 10.1038/nm.4275.

Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus. Plissonnier ML, Lahlali T, Raab M, Michelet M, Romero-López C, Rivoire M, Strebhardt K, Durantel D, Levrero M, Mehlen P, Zoulim F, Parent R. Oncogene. 2017 Nov;36(48):6712-6724. doi: 10.1038/onc.2017.271.

Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells. Plissonnier ML, Fauconnet S, Bittard H, Mougin C, Rommelaere J, Lascombe I.  Oncotarget. 2017 Nov; 8(64):107744-107762.  doi: 10.18632/oncotarget.22632.

Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Lucifora J,…, Levrero M,…, Durantel D. Antiviral Res. 2017 Sep;145:14-19. doi: 10.1016/j.antiviral.2017.07.006.

Metformin-inducedablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Pulito C,…, Levrero M,…, Blandino G. Cell Discov. 2017 Jul;3:17022. doi: 10.1038/celldisc.2017.22. 

Plasmodium P36 determines host cell receptor usage during sporozoite invasion. Manzoni G.,…, Zeisel MB,…, Silvie O. eLife. 2017 May;6. pii: e25903. doi: 10.7554/eLife.25903.

Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma. Holmila R, Sklias A, Muller DC, Degli Esposti D, Guilloreau P, Mckay J, Sangrajrang S, Srivatanakul P, Hainaut P, Merle P, Herceg Z, Nogueira da Costa A. PLoS One. 2017 Mar 23;12(3):e0174265. doi: 10.1371/journal.pone.0174265.

DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection. Fan H, Cui Z, Zhang H, Mani SK, Diab A, Lefrancois L, Fares N, Merle P, Andrisani O. Oncogene. 2017 Apr 27;36(17):2435-2445. doi: 10.1038/onc.2016.399.

Polymorphic multiple hepatocellular adenoma including a non-steatotic HNF1α-inactivated variant. Mohkam K, Darnis B, Cazauran JB, Rode A, Manichon AF, Ducerf C, Bancel B, Mabrut JY. Hepatobiliary Pancreat Dis Int. 2017 Oct 15;16(5):552-555. doi: 10.1016/S1499-3872(17)60058-4.

Relevance of the porcine model of hepatectomy for studying portal inflow modulation by splenectomy. Darnis B, Mohkam K, Mabrut JY. J Surg Res. 2017 Sep;217:232-234. doi: 10.1016/j.jss.2017.02.074.

Challenges to a Cure for HBV Infection. Testoni B, Levrero M, Zoulim F. Semin Liver Dis. 2017 Aug;37(3):231-242. doi: 10.1055/s-0037-1606212. Review.

Advancing the clinical development of hepatitis C virus host-targeting agents. Zeisel MB and Baumert TF. The Lancet. 2017 Feb;389(10070):674-675. doi: 10.1016/S0140-6736(17)30043-0. Review.

Towards novel immunocompetent animal models for hepatitis B virus infection. Mailly L, Zeisel MB, Baumert TF. Hepatology. 2017 Sep;66(3):691-693. doi: 10.1002/hep.29249. Review.

2016

Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B patients. Lebossé F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, Hervieu V, Berthillon P, Berby F, Bordes I, Durantel D, Levrero M, Lampertico P, Zoulim F. J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30757-7. doi: 10.1016/j.jhep.2016.12.024.

HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes. Alfaiate D, Lucifora J, Abeywickrama-Samarakoon N, Michelet M, Testoni B, Cortay JC, Sureau C, Zoulim F, Dény P, Durantel D. Antiviral Res. 2016 Dec;136:19-31. doi: 10.1016/j.antiviral.2016.10.006.

Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Testoni B, Durantel D, Lebossé F, Fresquet J, Helle F, Negro F, Donato MF, Levrero M, Zoulim F. Gut. 2016 Apr;65(4):672-82. doi: 10.1136/gutjnl-2014-309011.

Solute carrier NTCP regulates innate antiviral immune responses targeting hepatitis C virus infection of hepatocytes. Verrier ER, Colpitts CC,…, Zeisel MB, Baumert TF. Cell Rep. 2016 Oct 25;17(5):1357-1368. doi: 10.1016/j.celrep.2016.09.084.

Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin. Tawar RG, Heydmann L, Bach C, Schüttrumpf J, Chavan S, King BJ, McClure CP, Ball JK, Pessaux P, Habersetzer F, Bartenschlager R, Zeisel MB, Baumert TF. Hepatology. 2016 Nov;64(5):1495-1506. doi: 10.1002/hep.28767.

Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis. Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB. J Virol. 2016 Jun 24;90(14):6387-6400. doi: 10.1128/JVI.00619-16.

A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. Verrier ER, Colpitts CC, .. Zeisel MB, Baumert TF. Hepatology. 2016 Jan;63(1):35-48. doi: 10.1002/hep.28013.HBV cure: why, how, when? Levrero M, Testoni B, Zoulim F. Curr Opin Virol. 2016 Jun;18:135-43. doi: 10.1016/j.coviro.2016.06.003.

The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells. Nunn AD, Scopigno T, Pediconi N, Levrero M, Hagman H, Kiskis J, Enejder A. Sci Rep. 2016 Jun 20;6:28025. doi: 10.1038/srep28025.

EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes. Mani SK, Zhang H, Diab A, Pascuzzi PE, Lefrançois L, Fares N, Bancel B, Merle P, Andrisani O. J Hepatol. 2016 Nov;65(5):888-898. doi: 10.1016/j.jhep.2016.05.022.

RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis. Zhang H, Xing Z, Mani SK, Bancel B, Durantel D, Zoulim F, Tran EJ, Merle P, Andrisani O. Hepatology. 2016 Oct;64(4):1033-48. doi: 10.1002/hep.28698.

Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing. Esposti DD, Hernandez-Vargas H, Voegele C, Fernandez-Jimenez N, Forey N, Bancel B, Le Calvez-Kelm F, McKay J, Merle P, Herceg Z. Oncotarget. 2016 May 31;7(22):31862-77. doi: 10.18632/oncotarget.7364.

HBx triggers either cellular senescence or cell proliferation depending on cellular phenotype. Idrissi ME, Hachem H, Koering C, Merle P, Thénoz M, Mortreux F, Wattel E. J Viral Hepat. 2016 Feb;23(2):130-8. doi: 10.1111/jvh.12450.

Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9). Gaymard A, Charles-Dufant A, Sabatier M, Cortay JC, Frobert E, Picard C, Casalegno JS, Rosa-Calatrava M, Ferraris O, Valette M, Ottmann M, Lina B, Escuret V. J Antimicrob Chemother. 2016 Nov;71(11):3036-3045.

Current treatments for chronic hepatitis B virus infections. Zoulim F, Lebossé F, Levrero M. Curr Opin Virol. 2016 Jun;18:109-16. doi: 10.1016/j.coviro.2016.06.004. Review.

Aiming for cure in HBV and HDV infection. Petersen J, Thompson AJ, Levrero M. J Hepatol. 2016 Oct;65(4):835-48. doi: 10.1016/j.jhep.2016.05.043. Review.

Mechanisms of HBV-induced hepatocellular carcinoma. Levrero M, Zucman-Rossi J. J Hepatol. 2016 Apr;64(1 Suppl):S84-101. doi: 10.1016/j.jhep.2016.02.021. Review.

Porcine models for the study of small-for-size syndrome and portal inflow modulation: literature review and proposal for a standardized nomenclature. Mohkam K, Darnis B, Mabrut JY. J Hepatobiliary Pancreat Sci. 2016 Nov;23(11):668-680. doi: 10.1002/jhbp.396. Review.

The hepatitis D satellite virus of hepatitis B virus: half-opening a new era to control viral infection? Abeywickrama-Samarakoon N, Cortay JC, Dény P. Curr Opin Infect Dis. 2016 Dec;29(6):645-653. Review.

Cell culture models for the investigation of hepatitis B and D virus infection. Verrier ER, Colpitts CC, Schuster C, Zeisel MB, Baumert TF. Viruses. 2016 Sep 20;8(9). pii: E261. Review.

 Hepatitis B virus: is a cure possible? Zeisel MB, Baumert TF. Expert Rev Clin Pharmacol. 2016 Sep;9(9):1129-30. doi: 10.1080/17512433.2016.1206466. Review.

2015

IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome. Palumbo GA, Scisciani C, Pediconi N, Lupacchini L, Alfalate D, Guerrieri F, Calvo L, Salerno D, Di Cocco S, Levrero M, Belloni L. PLoS One. 2015 Nov 18;10(11):e0142599. doi: 10.1371/journal.pone.0142599.

Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. Luangsay S, Ait-Goughoulte M, Michelet M, Floriot O, Bonnin M, Gruffaz M, Rivoire M, Fletcher S, Javanbakht H, Lucifora J, Zoulim F, Durantel D. J Hepatol. 2015 Nov;63(5):1077-85. doi: 10.1016/j.jhep.2015.06.022. 

Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing. Vaca-Paniagua F, Oliver J, Nogueira da Costa A, Merle P, McKay J, Herceg Z, Holmila R. Epigenomics. 2015;7(3):353-62. doi: 10.2217/epi.14.94.

PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models. Guillot C, Favaudon V, Herceg Z, Sagne C, Sauvaigo S, Merle P, Hall J, Chemin I. BMC Cancer. 2014 Aug 20;14:603. doi: 10.1186/1471-2407-14-603.

Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. da Costa AN, Plymoth A,..., Merle P, Beretta L, Hainaut P. Int J Cancer. 2015 Jan 1;136(1):172-81. doi: 10.1002/ijc.28953.

Subtotal hepatectomy in swine for studying small-for-size syndrome and portal inflow modulation: is it reliable? Darnis B, Mohkam K, Schmitt Z, Ledochowski S, Vial JP, Duperret S, Vogt C, Demian H, Golse N, Mezoughi S, Ducerf C, Mabrut JY. HPB (Oxford). 2015 Oct;17(10):881-8. doi: 10.1111/hpb.12434.

Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response. Chapellier M, Bachelard-Cascales E,..., Caron de Fromentel C, Caux C, Blay J-Y, Iggo R, Maguer-Satta V. Stem Cell Reports. 2015 Feb 10;4(2):239-54. doi: 10.1016/j.stemcr.2014.12.007.

Protein-peptide arrays for detection of specific anti-hepatitis D virus (HDV) genotype 1, 6, and 8 antibodies among HDV-infected patients by surface plasmon resonance imaging. Villiers MB, Cortay JC,..., Dény P. J Clin Microbiol. 2015 Apr;53(4):1164-71. doi: 10.1128/JCM.03002-14.

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F. Gut. 2015 Aug;64(8):1314-26. doi: 10.1136/gutjnl-2014-308943. Review.

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :